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Hereditary Non-Polyposis colon cancer
LADevlin, JH Price, PJ Morrison
INTRODUCTION
Colorectalcanceristhesecondmostcommoncause
ofcancerrelated deathandthethirdmostcommon
cancer in the United Kingdom.1 2 Around 80% of
cases present with spread to the bowel wall. Early
diagnosis andrecognition ofsymptoms cannowbe
achievedby screening asymptomatic persons.3
We now know that between 5-15% of colorectal
cancer is hereditary in nature. Various genetic
disorders exist that predispose individuals to
colorectal cancer (CRC), including Familial
Adenomatous Polyposis (Gardner's syndrome,/
Turcot's syndrome), Peutz-Jeghers syndrome,
Juvenile Polyposis syndrome and Hereditary Non
Polyposis Colorectal Cancer (HNPCC).
This is an autosomal dominant highly penetrant
cancer-susceptibilitysyndromecausedbygermline
mutationsinoneoftheDNAmismatchrepairgenes,
MLH1,MSH2,MSH6,PMS2andPMS1. Affected
individualshaveapredispositiontodevelopingearly
onsetcolorectalcancerandendometrialcancer,and
less commonly ovarian, small intestine, stomach,
biliary tract, pancreatic, brain and uroepithelial
tract cancer.
In contrast to Familial adenomatous polyposis and
other colorectal cancer syndromes, HNPCC lacks
distinctiveclinicalfeatures. Traditionallyassociated
with an increased susceptibility to CRC, the
extendingclinicalphenotypewithasusceptibilityto
othercancersmakesdiagnosisincreasinglydifficult.
Under-diagnosis leaves families susceptible to
cancer,whereas overdiagnosiscommitsfamiliesto
aprolonged screening program that is not without
its complications.
Various criteria have been developed to aid in
the diagnosis of HNPCC and select families for
molecular testing of mismatch repair genes, the
Amsterdam and Bethesda criteria being the most
widelyused(Boxes1-3).Difficultiesariseinfamilies
whodonotmeetthesecriteria,buthaveasignificant
history ofHNPCC related cancers.
HISTORICAL BACKGROUND
One of the first HNPCC families described was
"FamilyG",byWarthinin 1913. Warthin's interest
in the hereditary nature of certain cancers was
stimulated by the depressed thoughts from his
seamstress who had told him that she would die at
an early age from cancer ofthe colon, or cancer of
the female organs, ashadmanyofherrelatives. He
analysed3600casesofneoplasmatthepathological
laboratory ofthe University ofMichigan between
the years of 1895 to 1913. From looking at family
historiesheidentifiedthosewithmultipleoccurrence
of carcinoma. The incidence of cancer in these
families was so strikingthathe interpretedthemas
showing an inherited susceptibility to cancer.
Hisseamstresslaterdiedofendometrialcarcinoma,
butherfamily,"FamilyG" showedapredominance
ofuterine,gastricandcoloncancer.Warthin'sstudy
looked at three successive generations; forty-eight
descendants of a grandfather with cancer of the
stomach/intestine. Ten cases ofcarcinoma ofthe
uterus and seven ofthe stomach were described.
He noted that uterus, breast, gastrointestinal tract
andmoutharethepartsofthebodymostfrequently
involvedinthecaseofthesefamilycancers. Cancer
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ofthe lip and rodent ulcer ofthe face also show a
tendency to familial occurrence.
Lynch revisited the family in the 1960's,5 with
morethan650 descendants. Henotedtheincreased
incidences ofadenocarcinoma, predominantely of
the colon and endometrium. Oneparticularbranch
ofthefamily(fromasibshipoften,fromtheoriginal
progenitor)initiallyshowedapaucityofcanceruntil
furthergenerations developedchroniclymphocytic
leukaemia and lymphosarcoma (3 out of seven
members ofa sibship).
Severalmembersoftheotherbranchesofthefamily
also developed chronic lymphocytic leukaemia,
sarcomas and brain tumours.
Lynch concluded that the cancer family syndrome
was characterised by: (1) increased occurrences
of adenocarcinoma, primarily of the colon and
endometrium; (2) increased incidence ofmultiple
primary malignant neoplasms; (3) autosomal
dominant inheritance; and (4) early age of onset
ofcancer. "Family G" differed from other families
withthecancerfamilysyndromeinthedevelopment
of sarcomas and leukaemias in some family
members.
Henamedthepurelycolontype 'Lynchtype 1'and
familieswithextracoloniccancersincludingovarian
andendometrial, 'Lynchtype2'.Wenowknowthat
severalgenescausethedifferentphenotypesandthe
term HNPCC is generally used.
MOLECULAR GENETICS
HNPCC is causedbymutations inmismatchrepair
genes, MLH1, MSH2, MSH6, PMS2 and PMS1.
MLH1 and MSH2 account for the majority of
familieswithHNPCC. Theprevalenceofmutations
inthese two genes in HNPCC families depends on
thechosenpopulationandinclusioncriteriausedfor
molecular screening, but can be as high as 86%.6
Founder effects in this Finnish population may
accountfortherelativelyhighmutationdetectionrate
andtheprevalence ofMLH1 andMSH2 mutations
in other HNPCC kindreds meeting theAmsterdam
criteriahavebeen39-49%.7 Thesamestudiesfound
the prevalence ofMLH1 and MSH2 mutations in
kindreds who are "Amsterdam Like", showing
familial clustering of colorectal and other related
cancers, to be between 8 and 16.7%, depending on
thespecificsubgrouptested. Thepopulationcarrier
frequenciesofMLH1andMSH2havebeenestimated
at 1:3139 in the Scottishpopulation.9
Recently, it has been noted that large genomic
rearrangements, that traditionally would not be
pickedupongenomicsequencing,accountformore
than500%ofpathogenicmutationsinMLH1/MSH2
in families meeting theAmsterdam criteria.'0
MSH6 mutations are less common; 3.8% oftotal
families, and 14.7% of all families with DNA
mismatch repair gene mutations in a German
HNPCC cohort,1' hadMSH6 genemutations.They
hadalaterageofdiseaseonsetandalowerincidence
ofCRC,hencealmosttwo-thirdsoffamiliescarrying
MSH6 mutations would have been missed if the
Amsterdam criteria were applied as a 'checklist'to
be met prior to molecular testing.
A deletion in PMS2 and one nonsense mutation in
PMS1 have been described in HNPCC families,'2
however a more recent study by Liu et all3 failed
to identifyanyclearcutpathogenic mutations in 84
HNPCC andHNPCC likekindreds withoutknown
mutations inthe otherthreeknownDNAmismatch
repair genes.
At present, testing in the NHS is offered on a
diagnosticbasisforgermlinemutationsinMLHIand
MSH2tofamiliesfulfillingthemodifiedAmsterdam
criteria in mostregions.
Molecular analysis ofthese mismatchrepair genes
is expensive and very labour intense; therefore
selectionoffamiliesformolecularanalysisofMLH1
and MSH2 must be aimed at those likely to have a
mutation in either ofthe two genes.
NodefinitecriteriaexistforthediagnosisofHNPCC
andthere are various factors thatwill influence the
likelihood of a mutation in one of the mismatch
repair genes known to be involved.
DIAGNOSTIC CRITERIA
TheAmsterdamcriteriaweredevelopedin 1991 by
theInternationalCollaborativeGrouponHereditary
Non-polyposisColorectalCancer(ICG-HNPCC),14
in an attempt to standardise diagnostic criteria in
recruitment of HNPCC patients for comparative
multicentre studies. These were modified in 1999
to include other HNPCC related cancers.'5
Since then, the Amsterdam criteria have been
commonly used to diagnose HNPCC and to select
families formolecular analysis ofmismatchrepair
genes.
ApplicationoftheAmsterdamcriteriatomolecular
testing will increase the chance of a germline
mutation in MSH2 and MLH1, but may indeed
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miss a significant number offamilies carrying an
MSH6 mutation.
Box 1:
Box 2:
MICROSATELLITE INSTABILITY (MSI)AND
IMMUNOHISTOCHEMISTRY (IHC)
Microsatelliteinstabilityischaracteristicoftumours
from individuals with a mutation in one of the
mismatchrepair genes. These arelengthvariations
of short repetitive DNA sequences in the tumour,
and occur in more than 80% ofHNPCC tumours.
As many as 15% ofsporadic colorectal cancer also
display MSI.16
MSI can therefore be used as a screening tool to
try and identify patients who are likely to have
a mutation in one of these genes. The Bethesda
guidelines were introduced in 199717 to indicate
whichfamilies shouldproceedto MSItestingprior
to molecular analysis (Box 3).
TheseBethesdaGuidelines wererevisedinrelation
to their performance, sensitivity and specificity in
2002,followingaHNPCCworkshopattheNational
Cancer Institute, Bethesda, MD,.8 (Box 4).
Box 3:
Immunohistochemical loss of expression of the
affected MMR protein is another characteristic
feature ofHNPCC tumours. This too can be used
as a screening, in combination with MSI, prior to
molecular testing.
MSI and IHC have both been shown to be highly
sensitive and specific in predicting a germline
mutation (97 and 83%respectively forMSI, 79 and
89% respectively for IHC),19 and are reliable to
be used to identify patients suitable for molecular
analysis,inpatientssuspectedofHNPCC.20Tumours
resulting from a germline mutation in MSH6 may
exhibit a lower degree of MSI,21 and therefore
an MSI-low phenotype cannot be considered an
exclusion criterion for mutation testing ofMSH6.
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Amsterdam criteria I
Thereshouldbeatleastthreerelativeswithhistologically
verified CRC; all of the following criteria should be
present:
One should be a first degree relative ofthe other two:
At least two successive generations should be
affected:
At least one CRC should be diagnosed before age 50:
FAP should be excluded in the CRC case:
Tumours should be verified by pathological
examination.
TheBethesdacriteriaforMSItestingoftumours:tumours
from any ofthe following should be tested for MSI (or
by immunohistochemistry) and then positive patients
should continue for MMR testing.
Individuals with cancer in families that meet the
Amsterdam Criteria:
Individuals with two HNPCC-associated cancers,
including synchronous and metachronous CRC or
associated extracolonic cancers:
Individuals with CRC and a first-degree relative with
CRCand/orHNPCC-relatedextracoloniccancerand/or
a colorectal adenoma diagnosed at age <40 years:
Individuals with CRC orendometrial cancerdiagnosed
at age < 45 years:
IndividualswithrightsidedCRCwithanundifferentiated
pattern(solidorcribiform)onhistopathologydiagnosed
at age < 45 years:
Individuals with signet-ring-cell-type CRC diagnosed
at age <45 years:
Individuals with adenomas diagnosed at age < 40
years.
ModifiedAmsterdam criteria (Amsterdam II)
There are at least three relatives with an HiNPCC
associated cancer (large bowel, endometrium, small
bowel, ureter, or renal pelvis, though not including
stomach ovary, brain, bladder or skin):
One affected person is a first degree relative of the
other two:
At least two successive generations are affected:
At least one person was diagnosed before the age of
50 years:
Familial adenomatous polyposis has been excluded:
Tumours have been verified by pathological
examination.
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Box 4:
Revised Bethesda Guidelines for testing colorectal
tumours formicrosatelllite instability (MSI).
Tumours from individuals should be tested for MSI in
the following situations:
1) Colorectal cancerdiagnosedinapatientwhoisless
than 50 years ofage.
2) Presenceofsynchronous,metachronouscolorectal,
orotherHNPCCassociatedtumours*,regardlessof
age.
3) Colorectal cancer with the MSI-Ht histology$
diagnosed in apatient who is less than 60 years of
age-.
4) Colorectal cancer diagnosed in one or more first
degree relatives with an HNPCC-related tumour,
with one ofthe cancers being diagnosed less than
50 years.
5) Colorectal cancer diagnosed in two or more first-
or second-degree relatives with HNPCC-related
tumours, regardless ofage.
*HNPCC related tumours include colorectal, endometrial,
stomach,ovarian,pancreas,ureterandrenalpelvis,biliarytract,
and brain (usually glioblastoma as seen in Turcot syndrome)
tumours, sebaceousglandadenomasandkeratoacanthomasin
Muir-Torre syndrome, and carcinoma ofthe small bowel.
there was a 28% chance ofidentifying a germline
mutation in MLH1/MSH2 in an individual who
developed CRC less than 30 years.
Syngal et al calculated similar sensitivity of the
Amsterdam criteria for detecting a germline
mutation in MLH1/MSH2; 61% with a specificity
of67%. Higher sensitivities are howeverreported
for Amsterdam II and the Bethesda criteria; 78%
and 94% respectively.23
NoperfectcriteriaexistforthediagnosisofHNPCC
or indeed forpredicting the likelihood ofa MMR
gene mutation, and difficulty arises in trying to
obtain anadequatebalancebetweensensitivityand
specificity.
CANCER RISKASSOCIATEDWITH HNPCC
The lifetimeriskofany cancertomutationcarriers
inHNPCC is 91% formales, and69% forfemales,
with a 74% and 30% riskby age 70 for colorectal
cancerrespectivelyineach sex. Theriskofovarian
cancer in females (figure 1) is around 10% by age
70years,24 and endometrial canceraround 40%by
age 70 years (figure 2). MSH6 is associated with
a slightly different tumour phenotype (later age
of disease onset and lower incidence of CRC),'1
and an estimated lifetime cancer risk of 60%.25
Presentation may be with only endometrial cancer
in families and we have ascertained some cases
through gynaecology clinics.
tMSI-H =microsatellite instability-high intumours refers to
changes in two ormore ofthe five National Cancer Institute-
recommended panels ofmicrosatellite markers.
tPresence of tumour infiltrating lymphocytes, Crohn's-like
lymphocytic reactions, mucinous/signet-ring differentiation,
ormedullary growth pattem.
-There was no consensus among the Workshop participants
on whether to include the age criteria in guideline 3 above;
participants voted to keep less than 60 years of age in the
guidelines.
Fig 1. Ovarian cancer.
A review carried out by Grady calculated the
likelihoodofmutationdetectioninMLH1/MSH2in
HNPCC families depending onthe clinical criteria
used; The Amsterdam I criteria have the highest
predictive value forthe identification ofamutation
in MLH1 and MSH2 genes (40-60% likelihood of
mutation detection), but this is met only in larger
families.22The likelihood offinding amutation fell
to 18%fortheAmsterdamIIcriteria,andto20-30%
for the original Bethesda guidelines. Interestingly
GENETIC COUNSELLING
Guidelines exist for segregating colon cancer risk
into high (greaterthan 1 in 10), medium (less than
1 in 10 to 1 in 20), and low risk (less than 1 in 20
- - I in50(thepopulationlevel)-seetable1).Most
cancer genetic screening programs offer a"triage"
system ofreferrals where patients fill in a detailed
questionnaire to allow accurate confirmation of
cancersinthefamilyandthedrawingofanaccurate
familytree.Thisenablesthegeneticteamofclinical
© The UlsterMedical Society, 2005.
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Fig2. Endometrial cancer.
geneticist and genetic counsellors or genetic
associates to work out an accurate individual risk
forthe proband.
Confirmationofcancersisimportantfortworeasons.
Firstlysomepatientsmaynotknowtheexactcancers
theirrelatives suffered from, orwhetherthe cancer
from which they died was primary or secondary.
This is particularly important in patients with
ovarian and colon cancers when it is important to
distinguish which is the primary and which is the
secondarycancerorifthereareindeedtwoseparate
primaries(figure3),astherisktorelativeswillvary
depending on the number ofcancers in the family
as to and whether the family fits medium or high
risk screening criteria. Secondly some suspected
cancers may actually be benign (e.g. ovarian cysts
or endometrial fibroids), and the risk to the family
maybe very low.
Rarely,somepatientsmayfabricateafamilyhistory,
as they maybe suffering from otherproblems ofa
nonphysical nature, or to seek attention, and these
patients require special help in dealing with their
problems. We have had some cases in our own
practice, and GP's and surgeons should be aware
ofthe possibility that this may occur, even ifit is
uncommon.
If patients are in the low risk category after
preliminaryriskestimation,managementisusually
bytelephoneandwrittencontacttothepatientwith
copiestothe generalpractitioner, detailing thatthe
patient is atlowriskandgiving reassurance and an
offeroffurtherriskevaluation ifthe familyhistory
changes (e.g. another relative becomes affected).
Patients often find this very helpful, especially as
theydonotneedtoattendahospitalclinic. Medium
riskpatients areofferedscreening atanappropriate
Fig3. Ovarian cancer with resection of colorectal
tumour.
secondary level clinic with colonoscopy at defined
intervals. Often this will be an 'entry' and 'exit'
regime with initial colonoscopy at -35 years and
later colonoscopy at 50-55 years. This covers the
main time that polyps will grow in the colon and
allows prevention. High-risk patients are offered
a consultation with a geneticist for consideration
of genetic testing and a range of screening and
preventative measures including colonoscopy at 2
yearly intervals from 25, or 5 years younger than
the earliest affected case in the family (whichever
comes first), up to age 75 years.
SurveillanceprogrammesintheUKarebasedupon
astudycarriedoutbyagroup atLeidenUniversity,
Netherlands, who looked at 114 families with an
identified mismatch repair gene defect and/or met
the clinical criteria for HNPCC, and looked at the
intervalbetweensurveillanceandcolorectalcancer.26
They recommend colonoscopy with an interval of
not more than two years for HNPCC families.
1:1 1:2
Colon 45
11
11:1 11:2 11:3 11:4 11:5
colon6 6 Ov60
II
111:1 111:2 lll:3 111:4 111:5
Colon 54
Iv
rV.1
11:6 11:7 11:8
Endo58 Colon38
111:8
Fig 4. Pedigree showingtypical referral for HNPCC.
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TABLE I
Colorectal Cancer risks (population risk = I in 50)
FamilyHistory of
Colorectal Cancer Lifetime Risks Low Risk-
1 RELATIVE
>45 yrs I in 17 Yes
<45 yrs I in 10 Yes
2 RELATIVES
one 1st degree and one 2nd degree
two 1st degree relatives ave <60
two 1st degree relatives ave >70
1 in 12
1 in 6
1 in 10
3 OR MORE RELATIVES
dominantpedigree orAmsterdam 1 in 2 - 1 in 3
criteria IHNPCC family
Discussion ofthe ovarian cancer risk (population
risk 1 in 70 increasing to around 10-15% in cases
ofHNPCC)andendometrial cancerrisk(population
risk 1 in 75 increasing to around 30-40% in cases
of HNPCC, and may be higher in MSH6 genetic
mutations) is importantinfemaleswith ahistoryof
HNPCC. Ovariananduterineultrasoundwithpipelle
biopsy and CA125 tumour markers provide some
reassurance althoughclinicaltrials areunderway to
determinetheefficacyofthisscreening.Preventative
oophorectomy/hysterectomy, and other surgical
options are also discussed. Upper GI endoscopy
needstobeconsideredifthereis ahistoryofstomach
cancer in the family.
Thefamilytree(figure4)is atypicalreferralwiththe
index case, 111.3 (arrowed), being referred because
ofher family history which includes brother, 111.1,
with colon cancer at age 54, mother with ovarian
cancerage60,twomaternaluncleswithcoloncancer
(11.3 age 66 and 11.7 age 38) and a maternal aunt
with endometrial canceraged 58. The family fitthe
Amsterdamcriteriawith3affectedcasesofHNPCC
related cancer (CRC, endometrial cancer etc.), at
least one (here 2 cases) with colon cancerunder 50
and2 generationsbeingaffected. Genetictesting of
theindexcase's,brother 111.1,confirmed amutation
intheMSH2 gene consistentwithHNPCC. Carrier
testing was then offered to all family members and
theindexpatientwasshownnotto carrythemutation
although four ofher siblings (dot indicates carrier)
were found to be carriers ofthe mutation. This is
powerfulgeneticinformation astherisktotheindex
case isreducedto thepopulationriskof 1 in 50 (for
CRC), and no additional screening is necessary for
eitherher orherchildren(she cannot pass on a gene
mutation she does not have). Her siblings, who are
carriers, should have 2 yearly colonoscopies from
25 yearsandhertwocarriersisters shouldalsohave
endometrial and ovarian screening starting in their
mid thirties.
Following genetic testing, if a mutation is found
in a HNPCC family, other at risk family members
should be offered testing as in the example above.
Ifthey prove tobenegative forthe familymutation,
then further surveillance is not necessary, but it
is important that they should be reminded that a
background population risk for colorectal cancer
still exists and lifestyle measures including a diet
including fruit and vegetables and exercise may be
helpful. Otherissues including insurance risks can
The Ulster Medical Society, 2005.
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be covered although this is less ofaproblem inthe
United Kingdom as there is a moratorium on the
useofgenetictests,27whichwasextendedinMarch
2005 from 5 to 10years inaconcordatbetweenthe
insurance industry andthe government andwill be
reviewed in 2008 before the 10 year moratorium
ends inNovember 2011.28
Families inwhich amutation is not identified need
to continue with ongoing surveillance until future
genetictestingeventuallyallowsclarificationofthe
risks inthe familywithnewgenesbeingtestedfor
as they are found.
CONCLUSIONS
The diagnosis of HNPCC allows early detection
andpreventionofHNPCCrelatedcancers. Criteria
exist to aid diagnosis for HNPCC and also to aid
in selection of patients for molecular analysis of
mismatch repair genes, although such testing is
expensiveandlabourintense. Othercandidategenes
maybe involvedandmayaccountforfamilieswith
a phenotype not consistent with the Amsterdam
criteria, andthecurrentcriteriamayfailtodiagnose
families with MSH6 or otherrare mutations.
HNPCC is an important condition relevant to the
practice of medical practitioners from various
specialties, particularly those who see and treat
cancer patients. The condition is complex and all
potential patients should be referred to a regional
clinical genetics departmentwhere full assessment
andcounselling oftheproband(andlaterthe entire
family)canbecarriedout,andscreeningprogrammes
instigated through onward referral to colonoscopy
services, or reassurance can be given in low risk
cases.
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